Biolidics Ltd. (8YY) AI Stock Analysis

• Market Cap: S$88.41M
• Dividend Yield: N/A
• Average Volume (3M): 412.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SG
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 1,733,441,800
• 10 Day Avg. Volume: 410,990
• 30 Day Avg. Volume: 412,950
• PEG Ratio: 0.66
• Price to Book (P/B): 58.30
• Price to Sales (P/S): 16.93
• P/FCF Ratio: -247.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: S$0.05 ▲(25.00% Upside)
• Action: Reiterated Date: 03/16/26
• Date: Action: Reiterated 03/16/26

The score is held down primarily by weak financial performance—persistent losses, negative free cash flow, and limited balance-sheet flexibility—despite a strong 2025 revenue rebound. Technical indicators add caution due to negative MACD and below-average near-term price action, while valuation is difficult to assess meaningfully given negative earnings and no dividend yield data.

Positive Factors

Revenue rebound / commercial traction

A near-200% revenue rebound to ~5.3m in 2025 indicates renewed commercial traction and product demand versus a weak prior year. If sustained, the larger revenue base can enable operating leverage, support investment in distribution, and reduce the firm's reliance on external funding over the medium term.

Recurring consumables business model

A business model built on test kits plus per-test consumables creates inherent repeat revenue once an installed base is established. Durable consumable demand supports revenue visibility, higher lifetime customer value, and margin sustainability as unit volumes scale across healthcare providers and laboratories.

Strategic focus in diagnostics (POC & molecular)

Focusing on point-of-care and molecular assays places the company in structural growth segments of healthcare diagnostics. Persistent demand for rapid and lab-based infectious disease testing underpins a sizable addressable market and supports long-term partnership, distribution, and scale opportunities.

Negative Factors

Persistent net losses

Despite revenue growth, a ~4.0m net loss in 2025 and consistent annual losses show the business has not reached sustainable profitability. Ongoing losses erode equity over time, limit retained-capital reinvestment, and mean the firm must demonstrate durable margin improvement to avoid recurrent capital raises that constrain strategic flexibility.

Negative operating and free cash flow

Persistent negative operating and free cash flow indicate the core business is not yet self-funding. Even with improvement, ongoing cash burn requires external financing or asset draws, increasing execution risk and potentially delaying reinvestment in commercialization or R&D until cash generation is reliably positive.

Thin equity and meaningful leverage

Debt near ~2.4m versus a thin equity cushion (~1.5m) and prior negative-equity years reduces financial flexibility. Limited balance-sheet headroom raises refinancing and solvency risk if operating performance weakens, and increases the likelihood of dilutive capital raises or restrictive covenants that can hamper long-term strategic initiatives.

Biolidics Ltd. Business Overview & Revenue Model

Company Description

Embracing Future Holdings Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Japan, Hong Kong, Thailand, Malaysia, and the United States. It operates through Cancer, Infectious Diseases, and Laboratory Services segments. The company offers ClearCell FX1 System that includes Streck Cell-free DNA BCT and EDTA tubes, a fully automated device for cell retrieval that can separate wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood; and CTChip FR1 biochip that isolate the CTCs from leukocytes. It also provides laboratory services. The company was formerly known as Biolidics Limited and changed its name to Embracing Future Holdings Limited in June 2025. The company was incorporated in 2009 and is based in Singapore.

How the Company Makes Money

Biolidics makes money primarily by selling diagnostic products and related consumables to healthcare providers, laboratories, distributors, and institutional buyers. Key revenue streams typically include (1) product sales of test kits (e.g., rapid antigen/antibody-style formats where applicable) and (2) recurring sales of consumables used per test (which can create repeat purchasing when installed users continue testing). The company may also generate revenue through distribution arrangements and collaborations where third parties market, resell, or help manufacture Biolidics-branded products, and through contract-based supply to institutions when awarded. Specific breakdown of revenue by product line, margins, named partnerships, and the relative contribution of instrument/platform sales versus consumables is null.

Biolidics Ltd. Financial Statement Overview

Summary

Revenue rebounded sharply in 2025, but the business remains loss-making with volatile margins, negative operating/free cash flow, and a balance sheet showing meaningful leverage versus a thin equity cushion (including a history of negative equity).

Income Statement

The top line rebounded sharply in 2025 (annual revenue up ~197% to ~5.3m from a very low 2024 base), showing renewed demand or improved commercialization. However, profitability remains weak: the company is still loss-making with negative operating profit and negative net income in every year provided (e.g., 2025 net loss ~4.0m), implying the business has not yet reached sustainable scale. Margins were volatile across years, reinforcing that earnings quality and operating leverage are still unproven.

Balance Sheet

Leverage is meaningful relative to the company’s capital base, with debt rising to ~2.4m in 2025 and equity thinning to ~1.5m (down from ~1.7m in 2024). Earlier periods also show balance-sheet instability, including years with negative equity (2022–2023), which is a key risk flag even if subsequently repaired. While total assets increased to ~5.1m in 2025, the combination of recurring losses and only modest equity cushion leaves limited flexibility if operating performance does not improve.

Cash Flow

Cash generation remains a core weakness: operating cash flow and free cash flow are negative across the period, including 2025 at roughly -0.36m (an improvement versus 2024’s ~-2.3m but still outflow). Free cash flow growth is also negative in 2025, indicating the path to self-funding operations is not yet established. Overall, the company continues to rely on external funding or balance-sheet resources to sustain operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.77M	5.26M	784.00K	277.00K	2.49M	2.31M
Gross Profit	490.00K	1.94M	187.00K	146.00K	1.16M	483.00K
EBITDA	-1.00M	-3.65M	-3.03M	-1.16M	-8.50M	-4.58M
Net Income	-1.04M	-3.96M	-3.43M	-2.49M	-9.37M	-5.98M
Balance Sheet
Total Assets	4.80M	5.08M	4.67M	682.00K	6.09M	11.42M
Cash, Cash Equivalents and Short-Term Investments	300.00K	557.00K	295.00K	183.00K	5.03M	3.96M
Total Debt	2.52M	2.41M	1.75M	2.02M	3.01M	4.25M
Total Liabilities	3.69M	3.56M	2.94M	2.67M	7.78M	9.09M
Stockholders Equity	1.11M	1.53M	1.73M	-1.99M	-1.69M	2.33M
Cash Flow
Free Cash Flow	-2.69M	-360.00K	-2.32M	-1.97M	-3.16M	-5.20M
Operating Cash Flow	-2.68M	-360.00K	-2.31M	-1.97M	-3.06M	-4.64M
Investing Cash Flow	-5.00K	0.00	-5.00K	-2.69M	5.00K	-860.00K
Financing Cash Flow	2.83M	623.00K	2.36M	-200.00K	4.18M	-1.15M

Biolidics Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:8YY, the sentiment is Neutral. The current price of 0.04 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.46 is Neutral, neither overbought nor oversold. The STOCH value of 64.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SG:8YY.

Biolidics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1B1	67 Neutral	S$53.83M	5.19	34.20%	3.37%	1.58%	115.29%
569	58 Neutral	S$46.51M	-19.74	-3.22%	―	13.07%	-70.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
42C	48 Neutral	S$217.76M	―	-450.81%	―	30.34%	17.14%
8YY	42 Neutral	S$88.41M	-14.38	-300.34%	―	―	―